What are the benefits of Amaxa™ Nucleofection™ over standard electroporation?


One major benefit of the Nucleofector™ Technology is that the nucleic acids are transferred directly into the nucleus enabling the transfection of non-dividing cells and an early analysis of transgene expression (depending on the protein) in as little as 2-4 hours. Furthermore, this method enables the transfection of primary cells with high efficiencies. In contrast to electroporation, the viability of the transfected cells is very high. Lonza offers a range of Amaxa™ Optimized Protocols, which are ready-to use. With standard electroporation you have to optimize the conditions on your own, which can be very time consuming.